The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.
The company has contracted with a urologist, who will review customers' requests for tests, and prescribe the firm's epigenetics-based male fertility analysis.
The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.
Loci identified in a genome-wide association study of women with spontaneous fraternal twin birth offers clues to the hormonal processes behind this propensity.
The test uses Illumina arrays to measure genome-wide sperm DNA methylation patterns in order to predict male fertility status and resulting embryo quality.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
